NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.46

+0.01 (+2.21%)

(As of 10/3/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.44
▼
$0.46
50-Day Range: $0.39
▼
$0.82
52-Week Range: $0.36
▼
$1.89

Volume: 63,860 shs
Average Volume: 492,738 shs
Market Capitalization: $40.92 million

P/E Ratio: 11.56
Dividend Yield: N/A
Price Target: N/A

Lipocine MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
2.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.45
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$41,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.14) to ($0.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

875th out of 1,093 stocks

Pharmaceutical Preparations Industry

433rd out of 548 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Lipocine.

2.0

Short Interest

Percentage of Shares Shorted
2.22% of the float of Lipocine has been sold short.
Short Interest Ratio / Days to Cover
Lipocine has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Lipocine has recently increased by 4.37%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Lipocine does not currently pay a dividend.
Dividend Growth
Lipocine does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LPCN.

2.5

News and Social Media Coverage

News Sentiment
Lipocine has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Lipocine this week, compared to 1 article on an average week.
Search Interest
2 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Lipocine is held by insiders.
Percentage Held by Institutions
Only 13.45% of the stock of Lipocine is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Lipocine are expected to grow in the coming year, from ($0.14) to ($0.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lipocine is 11.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.43.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lipocine is 11.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.45.
Price to Book Value per Share Ratio
Lipocine has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

September 28, 2022 | americanbankingnews.com

Lipocine Inc. (NASDAQ:LPCN) CEO Mahesh V. Patel Acquires 100,000 Shares

September 27, 2022 | finance.yahoo.com

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

September 27, 2022 | seekingalpha.com

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% - Seeking Alpha

September 27, 2022 | americanbankingnews.com

Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

September 26, 2022 | finance.yahoo.com

Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets

September 26, 2022 | finance.yahoo.com

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

September 23, 2022 | finance.yahoo.com

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Yahoo Finance

September 22, 2022 | finance.yahoo.com

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

September 16, 2022 | finance.yahoo.com

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo Finance

September 15, 2022 | nasdaq.com

Lipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - Nasdaq

September 15, 2022 | benzinga.com

Lipocine (NASDAQ:LPCN) – Lipocine Announces Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depressi - Benzinga

September 15, 2022 | finance.yahoo.com

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

August 10, 2022 | finance.yahoo.com

LPCN: TLANDO Launched

August 9, 2022 | finance.yahoo.com

Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

August 8, 2022 | apnews.com

Lipocine: Q2 Earnings Snapshot

August 8, 2022 | benzinga.com

Recap: Lipocine Q2 Earnings - Benzinga

August 8, 2022 | streetinsider.com

Form 10-Q Lipocine Inc. For: Jun 30 - StreetInsider.com

August 8, 2022 | seekingalpha.com

Lipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M (NASDAQ:LPCN) - Seeking Alpha

August 8, 2022 | streetinsider.com

Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com

August 8, 2022 | finance.yahoo.com

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

July 11, 2022 | nasdaq.com

S&P 500 Bear Market: Is Now the Right Time to Buy Stocks? - Nasdaq

July 11, 2022 | rttnews.com

Lipocine Says FDA Oks LPCN 2101 IND For Adult Epilepsy Treatment - RTTNews

July 11, 2022 | nasdaq.com

Arcutis Says Health Canada Accepts For Review Roflumilast Cream NDS For Plaque Psoriasis - Nasdaq

July 11, 2022 | nasdaq.com

Prepare to Pay More at Costco for This Reason - Nasdaq

June 14, 2022 | finance.yahoo.com

LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings: 8/08/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LPCN
CUSIP: N/A
CIK: 1535955
Web: www.lipocine.com
Phone: (801) 994-7383
Fax: 801-994-7388
Employees: 13
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.04
Trailing P/E Ratio: 11.56
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-630,000.00
Net Margins: N/A
Pretax Margin: 20.57%
Return on Equity: 8.52%
Return on Assets: 7.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.23
Quick Ratio: 22.23

Sales & Book Value

Annual Sales: $16.14 million
Price / Sales: 2.54
Cash Flow: $0.05 per share
Price / Cash Flow: 10.23
Book Value: $0.52 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 88,511,000
Free Float: 83,908,000
Market Cap: $40.92 million
Optionable: Optionable
Beta: 0.60

Key Executives

Dr. Mahesh V. Patel Ph.D. (Age 65)
Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO
Comp: $681.52k

Mr. Morgan R. Brown CPA (Age 54)
CPA, M.B.A., MBA, Corp. Sec.
Comp: $472.45k

Mr. Nachiappan Chidambaram Ph.D. (Age 53)
VP of Product Devel.
Comp: $323.22k

Mr. Logan Morse (Age 52)
VP of Sales, Marketing & Operations

Ms. Krista Fogarty (Age 54)
Principal Accounting Officer & Corp. Controller

Dr. Anthony DelConte M.D. (Age 64)
M. D., Chief Medical Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LPCN Stock - Frequently Asked Questions

How have LPCN shares performed in 2022?: Lipocine's stock was trading at $0.9911 at the start of the year. Since then, LPCN stock has decreased by 53.4% and is now trading at $0.4623.
View the best growth stocks for 2022 here.
When is Lipocine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our LPCN earnings forecast.
How were Lipocine's earnings last quarter?: Lipocine Inc. (NASDAQ:LPCN) released its earnings results on Monday, August, 8th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The specialty pharmaceutical company earned $0.50 million during the quarter, compared to the consensus estimate of $0.30 million.
What other stocks do shareholders of Lipocine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).

What is Lipocine's stock symbol?: Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How do I buy shares of Lipocine?: Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lipocine's stock price today?: One share of LPCN stock can currently be purchased for approximately $0.46.
How much money does Lipocine make?: Lipocine (NASDAQ:LPCN) has a market capitalization of $40.92 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.
How can I contact Lipocine?: Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lipocine - LPCN Stock Forecast, Price & News

Lipocine MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Lipocine (NASDAQ:LPCN) Stock

LPCN Stock News Headlines

LPCN Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LPCN Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™